JP Morgan Chase
TRDA icon

JP Morgan Chase’s Entrada Therapeutics TRDA Stock Holding History

JP Morgan Chase’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Buy
496,457
+481,610
+3,244% +$4.62M ﹤0.01% 3686
2026
Q1 		$175K Sell
14,847
-55,914
-79% -$641K ﹤0.01% 5540
2025
Q4 		$727K Sell
70,761
-63,117
-47% -$532K ﹤0.01% 4800
2025
Q3 		$776K Buy
133,878
+117,844
+735% +$689K ﹤0.01% 4762
2025
Q2 		$108K Buy
16,034
+1,328
+9% +$10.7K ﹤0.01% 5570
2025
Q1 		$133K Sell
14,706
-20,764
-59% -$259K ﹤0.01% 5428
2024
Q4 		$613K Buy
35,470
+24,658
+228% +$447K ﹤0.01% 4928
2024
Q3 		$173K Buy
10,812
+242
+2% +$3.81K ﹤0.01% 5471
2024
Q2 		$151K Buy
10,570
+2,157
+26% +$30.7K ﹤0.01% 5303
2024
Q1 		$119K Sell
8,413
-5,741
-41% -$81.2K ﹤0.01% 5597
2023
Q4 		$214K Sell
14,154
-427
-3% -$6.33K ﹤0.01% 5358
2023
Q3 		$230K Sell
14,581
-2,069
-12% -$32.6K ﹤0.01% 4982
2023
Q2 		$252K Buy
16,650
+8,110
+95% +$112K ﹤0.01% 4944
2023
Q1 		$124K Buy
8,540
+947
+12% +$12.6K ﹤0.01% 5332
2022
Q4 		$103K Buy
+7,593
New +$133K ﹤0.01% 5347
2022
Q2 		– Sell
-4,934
Closed -$46K – 6898
2022
Q1 		$46K Buy
4,934
+1,440
+41% +$15.4K ﹤0.01% 5826
2021
Q4 		$60K Buy
+3,494
New +$84.7K ﹤0.01% 5879

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

JP Morgan Chase's TRDA Position: Q2 2026 in Review

JP Morgan Chase increased its Entrada Therapeutics (TRDA) stake by 3,244% in Q2 2026, buying an estimated $4.62M and bringing the position to 496,457 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

JP Morgan Chase first reported a position in TRDA in Q4 2021 and has held it in 17 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • JP Morgan Chase held 496,457 shares of Entrada Therapeutics worth $3.83M as of Q2 2026.
  • JP Morgan Chase bought 481,610 Entrada Therapeutics shares in Q2 2026, an estimated $4.62M.
  • Entrada Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3686 holding.
  • JP Morgan Chase first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.